دورية أكاديمية
أعرض في EDS

Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity.

التفاصيل البيبلوغرافية
العنوان: Humanized Patient-derived Xenograft Models of Disseminated Ovarian Cancer Recapitulate Key Aspects of the Tumor Immune Environment within the Peritoneal Cavity.
المؤلفون: Steinkamp MP; Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico.; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico., Lagutina I; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico., Brayer KJ; Analytical and Translational Genomics Shared Resource, Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico., Schultz F; Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico., Burke D; Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico., Pankratz VS; Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, New Mexico.; Biostatistics Shared Resource, Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico., Adams SF; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico.; Department of Obstetrics and Gynecology, University of New Mexico School of Medicine, Albuquerque, New Mexico., Hudson LG; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico.; Department of Pharmaceutical Sciences, University of New Mexico School of Medicine, Albuquerque, New Mexico., Ness SA; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico.; Department of Molecular Genetics and Microbiology, University of New Mexico School of Medicine, Albuquerque, New Mexico., Wandinger-Ness A; Department of Pathology, University of New Mexico School of Medicine, Albuquerque, New Mexico.; Comprehensive Cancer Center, University of New Mexico, Albuquerque, New Mexico.
المصدر: Cancer research communications [Cancer Res Commun] 2023 Feb 22; Vol. 3 (2), pp. 309-324. Date of Electronic Publication: 2023 Feb 22 (Print Publication: 2023).
نوع المنشور: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
اللغة: English
بيانات الدورية: Publisher: American Association for Cancer Research Country of Publication: United States NLM ID: 9918281580506676 Publication Model: eCollection Cited Medium: Internet ISSN: 2767-9764 (Electronic) Linking ISSN: 27679764 NLM ISO Abbreviation: Cancer Res Commun
أسماء مطبوعة: Original Publication: [Philadelphia, Pennsylvania] : American Association for Cancer Research, [2021]-
مواضيع طبية MeSH: Peritoneal Cavity* , Ovarian Neoplasms*/therapy, Humans ; Mice ; Animals ; Female ; Heterografts ; Ascites ; Cytokines ; Tumor Microenvironment
مستخلص: The importance of the immune microenvironment in ovarian cancer progression, metastasis, and response to therapies has become increasingly clear, especially with the new emphasis on immunotherapies. To leverage the power of patient-derived xenograft (PDX) models within a humanized immune microenvironment, three ovarian cancer PDXs were grown in humanized NBSGW (huNBSGW) mice engrafted with human CD34 + cord blood-derived hematopoietic stem cells. Analysis of cytokine levels in the ascites fluid and identification of infiltrating immune cells in the tumors demonstrated that these humanized PDX (huPDX) established an immune tumor microenvironment similar to what has been reported for patients with ovarian cancer. The lack of human myeloid cell differentiation has been a major setback for humanized mouse models, but our analysis shows that PDX engraftment increases the human myeloid population in the peripheral blood. Analysis of cytokines within the ascites fluid of huPDX revealed high levels of human M-CSF, a key myeloid differentiation factor as well as other elevated cytokines that have previously been identified in ovarian cancer patient ascites fluid including those involved in immune cell differentiation and recruitment. Human tumor-associated macrophages and tumor-infiltrating lymphocytes were detected within the tumors of humanized mice, demonstrating immune cell recruitment to tumors. Comparison of the three huPDX revealed certain differences in cytokine signatures and in the extent of immune cell recruitment. Our studies show that huNBSGW PDX models reconstitute important aspects of the ovarian cancer immune tumor microenvironment, which may recommend these models for preclinical therapeutic trials.
Significance: huPDX models are ideal preclinical models for testing novel therapies. They reflect the genetic heterogeneity of the patient population, enhance human myeloid differentiation, and recruit immune cells to the tumor microenvironment.
(© 2023 The Authors; Published by the American Association for Cancer Research.)
References: Front Physiol. 2014 Mar 05;5:75. (PMID: 24634660)
Nat Biotechnol. 2014 Apr;32(4):364-72. (PMID: 24633240)
Stem Cell Reports. 2016 Oct 11;7(4):591-601. (PMID: 27618723)
J Immunol. 2020 Jul 1;205(1):272-281. (PMID: 32444392)
Stem Cell Reports. 2018 Apr 10;10(4):1175-1183. (PMID: 29576539)
Clin Cancer Res. 2002 Apr;8(4):1108-14. (PMID: 11948121)
Leukemia. 2021 Dec;35(12):3561-3567. (PMID: 33976371)
Front Oncol. 2017 Feb 22;7:24. (PMID: 28275576)
Front Oncol. 2019 May 22;9:421. (PMID: 31192126)
Cytokine. 2012 Aug;59(2):228-36. (PMID: 22595649)
Gynecol Oncol. 2020 Jan;156(1):222-232. (PMID: 31818495)
Cancer Discov. 2016 Feb;6(2):176-87. (PMID: 26631070)
J Immunother Cancer. 2020 Mar;8(1):. (PMID: 32217760)
Front Oncol. 2013 Dec 04;3:295. (PMID: 24363999)
Am J Pathol. 1997 May;150(5):1723-34. (PMID: 9137096)
J Hematol Oncol. 2016 Sep 21;9(1):92. (PMID: 27655386)
Oncoimmunology. 2017 May 11;6(8):e1320630. (PMID: 28919991)
Tumour Biol. 2015 Jun;36(6):4811-7. (PMID: 25647263)
Cancer Manag Res. 2018 Dec 05;10:6685-6693. (PMID: 30584363)
Stat Methods Med Res. 2018 Jun;27(6):1785-1805. (PMID: 27683581)
Anticancer Res. 2009 Aug;29(8):2875-84. (PMID: 19661290)
Front Immunol. 2016 Jan 20;7:2. (PMID: 26834744)
Front Oncol. 2014 Jun 06;4:137. (PMID: 24936477)
Gynecol Oncol. 2008 Aug;110(2):256-64. (PMID: 18547621)
Oncotarget. 2015 Sep 29;6(29):28327-40. (PMID: 26334103)
Stem Cell Reports. 2015 Feb 10;4(2):171-80. (PMID: 25601207)
J Immunother Cancer. 2020 Nov;8(2):. (PMID: 33177175)
Blood. 2011 Mar 17;117(11):3076-86. (PMID: 21252091)
Blood Adv. 2019 Feb 12;3(3):268-274. (PMID: 30696625)
Br J Cancer. 2016 Aug 23;115(5):553-63. (PMID: 27490802)
Front Oncol. 2020 Sep 24;10:569985. (PMID: 33072601)
Cancers (Basel). 2021 Dec 15;13(24):. (PMID: 34944908)
Sci Rep. 2015 Oct 06;5:14495. (PMID: 26440065)
Front Immunol. 2017 Nov 06;8:1482. (PMID: 29163543)
Am J Cancer Res. 2012;2(5):566-80. (PMID: 22957308)
Nat Rev Cancer. 2013 Apr;13(4):273-82. (PMID: 23426401)
Genome Biol. 2014 Mar 03;15(3):R46. (PMID: 24580807)
Proc Natl Acad Sci U S A. 2005 Dec 20;102(51):18538-43. (PMID: 16344461)
J Autoimmun. 2015 Aug;62:55-66. (PMID: 26143958)
Methods. 2013 Sep 1;63(1):41-9. (PMID: 23816787)
Immunol Res. 2011 Dec;51(2-3):170-82. (PMID: 22139852)
Proc Natl Acad Sci U S A. 2005 Oct 25;102(43):15545-50. (PMID: 16199517)
Anticancer Res. 2013 Nov;33(11):4785-90. (PMID: 24222114)
Chin Clin Oncol. 2015 Sep;4(3):30. (PMID: 26408297)
Gynecol Oncol. 1993 Apr;49(1):51-5. (PMID: 8482561)
Anticancer Res. 2006 Mar-Apr;26(2C):1715-8. (PMID: 16617566)
Blood. 2003 Aug 1;102(3):873-80. (PMID: 12689924)
Breast Cancer Res. 2018 Sep 5;20(1):108. (PMID: 30185216)
Obstet Gynecol Int. 2018 May 17;2018:1867238. (PMID: 29887891)
Clin Cancer Res. 2017 Mar 1;23(5):1263-1273. (PMID: 27573169)
Cell. 2021 Oct 14;184(21):5482-5496.e28. (PMID: 34597583)
Cancers (Basel). 2021 Jun 01;13(11):. (PMID: 34206004)
Clin Cancer Res. 2014 Mar 1;20(5):1288-97. (PMID: 24398046)
Oncoimmunology. 2015 Dec 10;5(3):e1090075. (PMID: 27141347)
Am J Pathol. 2010 Sep;177(3):1053-64. (PMID: 20651229)
J Leukoc Biol. 2019 Apr;105(4):741-753. (PMID: 30702754)
Oncoimmunology. 2018 Mar 15;7(5):e1424672. (PMID: 29721385)
PLoS One. 2017 May 1;12(5):e0176675. (PMID: 28459821)
FASEB J. 2018 Mar;32(3):1537-1549. (PMID: 29146734)
معلومات مُعتمدة: P30 CA118100 United States CA NCI NIH HHS; R24 OD035446 United States OD NIH HHS; R01 CA105257 United States CA NCI NIH HHS; R01 CA170250 United States CA NCI NIH HHS; R01 CA058443 United States CA NCI NIH HHS; R01 DE023222 United States DE NIDCR NIH HHS
المشرفين على المادة: 0 (Cytokines)
تواريخ الأحداث: Date Created: 20230302 Date Completed: 20230807 Latest Revision: 20240109
رمز التحديث: 20240109
مُعرف محوري في PubMed: PMC9973420
DOI: 10.1158/2767-9764.CRC-22-0300
PMID: 36860657
قاعدة البيانات: MEDLINE
الوصف
تدمد:2767-9764
DOI:10.1158/2767-9764.CRC-22-0300